104 223

Cited 6 times in

TMED9 Expression Level as a Biomarker of Epithelial Ovarian Cancer Progression and Prognosis

Authors
 Gwan Hee Han  ;  Hee Yun  ;  Joon-Yong Chung  ;  Jae-Hoon Kim  ;  Hanbyoul Cho 
Citation
 CANCER GENOMICS & PROTEOMICS, Vol.19(6) : 692-702, 2022-11 
Journal Title
CANCER GENOMICS & PROTEOMICS
ISSN
 1109-6535 
Issue Date
2022-11
MeSH
Biomarkers, Tumor / metabolism ; Carcinoma, Ovarian Epithelial / metabolism ; Cell Line, Tumor ; Cell Proliferation / genetics ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Neoplasms, Glandular and Epithelial* / genetics ; Ovarian Neoplasms* / pathology ; Prognosis ; RNA, Messenger / genetics
Keywords
TMED9 ; biomarker ; diagnosis ; ovarian cancer ; prognosis
Abstract
Background: Transmembrane emp24 domain-containing protein 9 (TMED9) belongs to the TMED/p24 family that transports, modifies, and packs proteins and lipids into vesicles for delivery to specific locations and is important in innate immune signaling via the endoplasmic reticulum-Golgi cargo pathway. TMED9 has been implicated in various cancer types; however, its role in epithelial ovarian cancer (EOC) is unclear. In this study, we aimed to elucidate the role and clinical significance of TMED9 in EOC.

Materials and methods: mRNA and protein levels of TMED9 and their associations with clinicopathological features in EOCs were evaluated using RNA-sequencing and immunohistochemistry data. Functional studies assessing the tumorigenic role of TMED9 in EOC cell lines were also performed.

Results: The mRNA expression of TMED9 was up-regulated in EOC compared to that in normal ovarian epithelium. TMED9 protein expression increased in progression from normal ovarian epithelium to EOC (p<0.001). Moreover, high expression of TMED9 was associated with advanced stage, serous cell type and poor histological grade in EOC and demonstrated independent prognostic significance for both disease-free and overall survival. Further functional studies showed that TMED9 knockdown reduced migration, invasion, cell proliferation, and colony formation of EOC cells.

Conclusion: Overall, our results support the use of TMED9 as a valuable prognostic biomarker and provide evidence for targeting of TMED9 as a novel strategy for EOC treatment.
Files in This Item:
T202205662.pdf Download
DOI
10.21873/cgp.20352
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jae Hoon(김재훈) ORCID logo https://orcid.org/0000-0001-6599-7065
Yun, Hee(윤희)
Cho, Hanbyoul(조한별) ORCID logo https://orcid.org/0000-0002-6177-1648
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/192749
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links